$GYGY

Game Your Game Inc. (GYGY): Entry into a Material Definitive Agreement

Game Your Game Inc. (GYGY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Game Your Game, Inc. Announces Direct Listing on Nasdaq - Common Stock to Begin Trading Under the Symbol “GYGY” PALO ALTO, Calif. — July 30, 2026 — Game Your Game, Inc. (“GYGY” or the “Company”), an AI-powered sports performance technology company focused on the golf

Original reporting
Published Jul 30, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$GYGY
Neutral
medium confidence
Mentioned
$GYGY
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GYGYNeutralMed
01

Why it matters

This 8-K discloses a material definitive agreement amending the note’s maturity and repayment mechanics, including retroactive effectiveness and waivers of certain default triggers. It also includes a letter agreement where the parent waives certain trigger events during a defined period around the direct listing.

02

Market read

The amendment changes the company’s debt covenant and repayment schedule, directly affecting perceived default risk and equity-credit linkage around the direct listing and the $4.00 share-price threshold.

03

What to watch

Traders should focus on how the repayment caps interact with the company’s ability to complete the direct listing and sell $40M of Series A preferred, since those milestones drive the repayment schedule and potential cash burn.

Relevance 6/10Novelty 7/10Timing: filed July 30, 2026, covering amendments effective retroactively to June 30, 2026

Background

The company previously issued an unsecured promissory note to its controlling parent affiliate (Grafiti LLC) and later structured a direct listing with a Series A convertible preferred exchange.

Company-level read

Ticker impact

$GYGYNeutralMedium confidence
Context

Game Your Game entered a Third Amendment and Waiver to its 10% note, extending maturity to July 31, 2027 and revising repayment caps tied to listing and share price.

Expected impact

Likely modest positive bias from lower default risk, but with added sensitivity to the $4.00 share-price threshold that governs monthly repayment caps.

Evidence & confidence

The filing is a primary disclosure (8-K) detailing new covenant mechanics: maturity extension, waiver of certain defaults, and repayment caps that tighten when the stock trades below $4.00. However, the excerpt does not provide the full economic terms or current outstanding balance beyond the principal amount, limiting precision on magnitude.

Market effects

For small-cap issuers with direct listings and related preferred structures, the filing highlights how debt repayment can be explicitly linked to listing progress and equity price levels.

No clear regional spillover beyond Nasdaq-listed small-cap credit and equity risk sentiment.

Limited global relevance; primarily affects the issuer’s capital structure and near-term refinancing/default risk.

Counterpoint

The maturity extension may be viewed as a sign of ongoing liquidity stress, and the $4.00 threshold could increase repayment constraints if the stock underperforms.

Key entities

  • Game Your Game, Inc.

    Nasdaq-listed company (GYGY) amending its unsecured promissory note and related preferred-stock trigger mechanics.

  • Grafiti LLC

    Affiliate of the controlling stockholder that holds the amended promissory note.

  • Grafiti Group LLC

    Parent and beneficial owner of more than 50% of the company’s common stock, party to the exchange and waiver arrangements.

  • Streeterville Capital, LLC

    Named in the repayment provisions as the party to the Securities Purchase Agreement for Series A convertible preferred stock.

Related articles

$CLVTHighAI 8/10

CLARIVATE PLC (CLVT): Other Events

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Clarivate Announces Pricing Terms of Offer to Purchase for Cash Certain of its Outstanding Debt Securities LONDON, September 23, 2026: Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the Reference Yi

$VMed

VISA INC. (V): Other Events

VISA INC. (V) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 18, 2026, Visa Inc. (the “Company”) authorized the deposit of $405 million into the U.S. litigation escrow account previously established under the Company’s U.S. retrospective responsibility plan (the “Plan”). Under the terms of the Plan, whe

$GOSSMedAI 8/10

Gossamer Bio, Inc. (GOSS): Other Events

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension (“P

$EVMNMedAI 9/10

Evommune, Inc. (EVMN): Regulation FD Disclosure

Evommune, Inc. (EVMN) filed an SEC Form 8-K — Regulation FD Disclosure. Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress Palo Alto, Calif., and New York, September 23, 2026 – Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical

$LGVNMedAI 8/10

Longeveron Inc. (LGVN): Other Events

Longeveron Inc. (LGVN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) ------------------- Company Announces Exploration of All Options to Maximize Shareholder Value ● Th